Assessment of antibodies against platelet factor 4 following vaccination with adenovirus type 26–vectored vaccines
Ad26.COV2.S and the other Ad26-vectored vaccines studied did not generally induce PF4 antibodies or increase preexisting PF4 antibody levels. Moreover, unlike VITT, TE events that occurred at any time following Ad26 vaccination were not associated with PF4 antibodies.
Authors
- Georgi Shukarev (ORCID: https://orcid.org/0000-0001-5154-7047)
- Hanneke Schuitemaker (ORCID: https://orcid.org/0000-0001-8563-2266)
- Hendy Kristyanto (ORCID: https://orcid.org/0000-0002-8022-6637)
- Jenny Hendriks (ORCID: https://orcid.org/0009-0008-8191-6200)
- Gert C. Scheper (ORCID: https://orcid.org/0000-0003-2316-756X)
- Roy van Heesbeen
- Jerald Sadoff (ORCID: https://orcid.org/0000-0002-4839-3013)
- Ilse Scheys
- Frank Struyf (ORCID: https://orcid.org/0000-0001-9988-0260)
- Leen Slaets (ORCID: https://orcid.org/0000-0002-5737-0550)
- Kerstin Lühn (ORCID: https://orcid.org/0000-0001-8451-1294)
- Esmée Braams
- Vicky Cárdenas
Institutions
- Janssen (Belgium) (BE)
- Janssen (United States) (US)
- Janssen (Netherlands) (NL)
Publication Details
- Journal
- Journal of Thrombosis and Haemostasis
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1016/j.jtha.2024.08.019
- Citations
- 4
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- Biomedical Advanced Research and Development Authority